SureTrader SureTrader
Home > Boards > US Listed > Medical - Equipment >

Neovasc, Inc. (NVCN)

Add NVCN Price Alert      Hide Sticky   Hide Intro
Moderator: CoinOp, steez, l2 hunter
Search This Board:
Last Post: 10/26/2016 7:04:39 PM - Followers: 53 - Board type: Free - Posts Today: 35


                                                                                   Nasdaq: NVCN

                                                                                      Contact Info
13562 Maycrest Way #5138, Richmond,

                                                                                  BC V6V 2j7 Canada
                                                                            Fax: 1.604.270.4384

                                                                      About Neovasc                                                                        

                                                     Neovasc Inc. is a specialty medical device company that develops, manufactures,
                                                     and markets products for the rapidly growing cardiovascular marketplace.

                                                                        Our products include the Tiara™ technology in development for the transcatheter
                                                                        treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
                                                                        refractory angina.

                                                                         A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
                                                                         publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
                                                                         Exchange TSX: (NVC) 


Neovasc Tiara

Tiara is a novel transcatheter device designed to treat mitral regurgitation (MR), a condition that is often severe and can lead to heart failure and death.

Neovasc is developing the Tiara for the treatment of severe MR, a condition that affects approximately four million patients in the U.S. alone. Currently, conventional surgical treatments are only appropriate for about 20% of these patients, leaving the majority of patients untreated.

The Tiara device is delivered through the apex of the heart to replace the mitral valve while preserving the integrity of the surrounding structures of the heart.

Tiara has been designed specifically to address each of the challenges listed below and meet the need for transcatheter replacement of the mitral valve, rather than being adapted from an aortic valve. Tiara implantation is achieved through a transapical approach and does not require any hemodynamic support.


Neovasc Reducer

An effective percutaneous treatment for refractory angina, a severely debilitating condition that affects millions globally.

Resulting from inadequate blood flow to the heart muscle, refractory angina (RA) can often cause recurrent and severe heart pain that may be difficult to manage through conventional drug, catheter, or surgical therapy.  RA patients typically experience significant disability and impaired quality of life with few options for relief or improvement in their symptoms.

The Neovasc Reducer has been shown to be a safe and effective treatment for RA. Using a procedure similar to a coronary stent implantation, the Reducer procedure uses standard catheter-based techniques.

As with any medical procedure, there are risks associated with the use of the Neovasc Reducer™ System, including but not limited to myocardial infarction, continued angina, and implant migration/dislodgement requiring medical intervention. For a complete list of complications, see the Instructions for Use.



Opko Investee Neovasc $9B Massive and Virtually Unpenetrated Market Opportunity

                                   ****   Leerink Partners Starts Neovasc (NVCN) at Outperform, $15 PT ****,+$15+PT/10390409.html

                                          Successfully increasing financing year to year through Institutional Public Offerings
                              sets a tone to a growing Value in its Marketplace.

                                                               6-k dated May 2014 

"For the three months ended March 31, 2014, net cash provided by financing activities was $24,658,642 compared to $194,010 for the same period in 2013. On March 26, 2014, the Company closed a bought deal equity financing underwritten by Cormark Securities Inc., which placed 4,192,000 common shares of Neovasc at a price of $6.00 per common share, for gross cash proceeds to the Company of $25,152,000. The share issue cost was $506,651." 

                                                                6-k dated May 2015 

"For the three months ended March 31, 2015, net cash provided by financing activities was $88,143,429, compared to $24,658,642 for the same period in 2014. On February 3, 2015, the Company closed an underwritten public offering of 12,075,000 common shares of the Company (of which 10,415,000 common shares were issued from treasury and 1,660,000 common shares were sold by certain directors, officers and employees of the Company) at a price per share of US$7.19 for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the selling security holders. The share issue costs incurred by the Company were $6,236,783. "

**NEWEST UPDATED INFO  6/15/16 - 6-K FILING SHOWS 81.28% Longs/Institutional Ownership from voting results**
(the “Company”)
Annual General Meeting of Shareholders
June 15, 2016
(Pursuant to Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations )
Common Shares represented at the Meeting:
Total issued and outstanding Common Shares as at Record Date:
Percentage of issued and outstanding Common Shares represented:


 May 4 ,2016 6-k filing here has  #1 holder with 22.1% " Dr. Phillip Frost" of Frost Gamma Investments Trust  
Shareholder Name   Number of Shares Held     Percentage of Issued Shares  
Frost Gamma Investments Trust      14,786,219       22.1 %


******Major Ownership Here: Funds & Institutions & Direct

Holders @Barrons has over

50+ Million Shares Owned !!! *****

****{ Major amount of this was purchased at the $6.00 & $7.00 level!! }

Outstanding Share Data 
August 9, 2016, the Company had 66,866,345 common voting shares issued and outstanding
"Remaining Non Dilutive to Shareholders as Direct Funding has been their proven successful funding arena"

August 6, 2015, the Company had 66,551,447 common shares issued and outstanding
August 12, 2014, the Company had 53,756,932 common voting shares issued and outstanding


Most recent broker ratings

05/20/2016 – Neovasc Inc. was downgraded to “neutral” by analysts at Ladenburg Thalmann.

03/30/2016 – Neovasc Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 9.5 price target on the stock.

10/07/2015 – JMP Securities began new coverage on Neovasc Inc. giving the company a “market outperform” rating. They now have a USD 10 price target on the stock.

09/23/2015 – Neovasc Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 20 price target on the stock.

03/31/2015 – Northland Securities began new coverage on Neovasc Inc. giving the company a “outperform” rating. They now have a USD 12 price target on the stock.

              ------------------>>>>>>>>>>>>>Recent deals involving mitral valve companies<<<<<<<<<<<<<<--------------
"Great info and a MUST READ on the demand and for acquisitions for these type of companies here from last year this month now that remainder or any legal issues are getting ironed out through the final appeals days now:"



  Neovasc the small cap medical device company has a promising set of catalysts approaching for its core tissue division and for its two life saving vascular devices, The Reducer and The Tiara. The Reducer recently released extremely positive top line results of its sham-controlled COSIRA trial, and full results should be released by the end of the month. The device is already CE marked in Europe, and is the first minimally invasive treatment for Refractory Angina. Based off of comparable devices, the device can be worth anywhere from $5.00 to $14.00 per share.

The Tiara has received an extremely broad patent for treating Mitral Regurgitation, and is the frontrunner in bringing an effective product to the market for the first time ever. Neovasc tested the device in animals and recently published strong data supporting the safety and efficacy of the device. The first human implantation is scheduled for Q1 of 2014. If approved and brought to market, this would be a billion dollar device.

Neovasc's Peripatch tissue division continues to boast strong growth and profit numbers, as shown in its latest quarterly filing. This profitable division should see increased revenues as more of Neovasc's customers gain FDA approval for their vascular devices that utilize Neovasc's Peripatch tissue. The profit generated from the tissue division funds the development of The Reducer and The Tiara, which is unique for a small medical company, which would usually have to rely on secondary offerings (dilution) to generate the necessary development funds. The expanding growth of Neovasc and its tissue division will not end anytime soon as they finalize the divestment of its low margin patch division and benefit from the rapidly growing heart valve market.

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NVCN News: Report of Foreign Issuer (6-k) 09:05 AM
NVCN News: Neovasc to Present Tiara and Reducer Data at TCT in Washington DC 07:00 AM
NVCN News: Neovasc to Present Tiara and Reducer Data at TCT in Washington DC 07:00 AM
NVCN News: Report of Foreign Issuer (6-k) 08/09/2016 04:07:28 PM
NVCN News: Neovasc Reports Second Quarter Results for 2016 08/09/2016 04:00:00 PM
News News Alert: Report of Foreign Issuer (6-k) 10/26/2016 09:05:20 AM
#1877  Sticky Note "Recent deals involving mitral valve companies" CoinOp 10/25/16 12:46:24 AM
#1857  Sticky Note NVCN $0.52 only 16m float / 66m O/S. l2 hunter 10/19/16 03:22:07 AM
#1917   I'm not a shareholder but this does look JT230 10/26/16 07:04:39 PM
#1916   * * $NVCN Video Chart 10-26-16 * * ClayTrader 10/26/16 05:26:06 PM
#1915   NVCN tomorrow next green day. $1 break now l2 hunter 10/26/16 04:36:02 PM
#1914   they are smashing this thing slyguy8888 10/26/16 03:58:22 PM
#1913   NVCN warming up today. Tomorrow next wave north. l2 hunter 10/26/16 03:52:21 PM
#1912   Great SS L8TR 10/26/16 03:44:00 PM
#1911   TY l2 hunter L8TR 10/26/16 03:37:00 PM
#1910   great entry. welcome on NVCN board. l2 hunter 10/26/16 03:35:11 PM
#1909   Adding here L8TR 10/26/16 03:30:43 PM
#1908   Looking sweet L8TR 10/26/16 03:26:36 PM
#1907   In june NVCN gapped open from .75 to CoinOp 10/26/16 03:24:03 PM
#1906   NVCN going into. Up trend start now. Hold l2 hunter 10/26/16 03:10:33 PM
#1905   NVCN 0,6580 + 17.63% harmsen 10/26/16 03:01:48 PM
#1904   Next resistance .68 jb55 10/26/16 02:58:25 PM
#1903   NVCN 0.63 +12.5% going into. new hod coming. l2 hunter 10/26/16 02:55:04 PM
#1902   ARCA noved off ask. Now at .6371 jb55 10/26/16 02:42:09 PM
#1901   yes, think we will see big turn deep l2 hunter 10/26/16 02:27:42 PM
#1900   ARCA has been holding this back for a while. jb55 10/26/16 02:24:38 PM
#1899   TCT Conference news now set in stone CoinOp 10/26/16 02:15:37 PM
#1898   looking solid here chou chou chou steez 10/26/16 01:49:52 PM
#1897   Looks like it is about to pop jb55 10/26/16 01:26:12 PM
#1896   NVCN looks strong. Close 0.63+× today. Early birds l2 hunter 10/26/16 01:12:25 PM
#1895   Whenever I'm entering @$0.6, it happens to pberger 10/26/16 12:00:07 PM
#1894   A little consolidation before the next level. jb55 10/26/16 11:12:49 AM
#1893   very nice chart patience this will go steez 10/26/16 10:59:15 AM
#1892   NVCN $0.6 only 16m float / 66m O/S. l2 hunter 10/26/16 10:41:14 AM
#1891   NVCN 2 blockbuster News ahead. The 10-Q in l2 hunter 10/26/16 10:26:17 AM
#1890   MCAD crossing zero line. Usually a good sign. jb55 10/26/16 10:20:33 AM
#1889   Go NVCN looking forward to getting back to Zenty 10/26/16 10:19:17 AM
#1888   Resistance .638 jb55 10/26/16 10:19:00 AM
#1887   NVCN way 1500% turn like my EBIO Biotech l2 hunter 10/26/16 09:56:38 AM
#1886   1st hours volume could surpass yesterday's volume. Nice. jb55 10/26/16 09:55:11 AM
#1885   Yes news are fine. Blockbuster news pending next l2 hunter 10/26/16 08:52:50 AM
#1884   Looks like we're gapping today. Tuedi 10/26/16 08:26:25 AM
#1883   NEWS >>> Neovasc to Present Tiara and Reducer l2 hunter 10/26/16 07:10:52 AM
#1882   Good day today jb55 10/25/16 04:02:59 PM
#1881   Yes, looks like NVCN will close above ma/50 l2 hunter 10/25/16 02:05:15 PM
#1880   looking good here today steez 10/25/16 01:54:20 PM
#1879   0.566 MA/50 is gone! Radar.. possible big news l2 hunter 10/25/16 10:00:30 AM
#1878   Today ma/50 breakout? l2 hunter 10/25/16 09:26:07 AM
#1877   "Recent deals involving mitral valve companies" CoinOp 10/25/16 12:46:24 AM
#1876   Got a nice connection someone noticed with the CoinOp 10/25/16 12:31:33 AM
#1875   agree, next week and the Q- earning in l2 hunter 10/24/16 12:06:30 PM
#1874   Clinical Trial Updates on Tiara on Monday 10/31 CoinOp 10/24/16 11:36:15 AM
#1873   NVCN looks awesome today. looks like we will l2 hunter 10/21/16 01:30:42 PM
#1872   yes great moving ahead , shows at the CoinOp 10/21/16 12:26:17 AM
#1871   Great NVCN DD. Thx for sharing l2 hunter 10/20/16 08:09:22 AM
#1870   In addition, yesterday/19th, NVCN filed new court papers! ttmasher 10/20/16 08:06:14 AM
#1869   MONDAY, OCTOBER 31, 2016, 2:00 PM - 6:00 PM CoinOp 10/20/16 04:03:46 AM
#1868   just 1 FDA NEWS or litle positive Q-earnings l2 hunter 10/19/16 01:06:51 PM